U.K. VC funding hits new high after bumper quarter

02 October 2018

Nick Paul Taylor / FierceBiotech

The British biotech sector enjoyed a big third quarter for VC financing. With more than £460 million ($600 million) in VC cash flowing into the bank accounts of U.K. biotechs, the sector has now raised 30% more money from public and private sources than it managed in all of last year. 

Trade group the UK BioIndustry Association (BIA) shared the data (PDF) in its quarterly update on the state of biotech financing in Britain. The BIA data show that British biotechs raised £732 million on public and private markets across June, July and August, bringing the total haul for the year up to £1.56 billion. Last year, the financing total topped out at £1.2 billion.

The VC figures compare favorably to recent history, too. Having raised £927 million in venture cash across the first eight months of 2018, British biotechs have already raised 80% more than in all of last year and 17% more than in 2015, the Immunocore-driven high point of U.K. VC funding. In a sign of how much U.K. biotech financing has changed in recent years, the amount of VC cash raised so far in 2018 is 30% more than the sector managed across 2012, 2013 and 2014, combined.

This strong performance is built on sizable investments in multiple companies. Whereas the figures for 2015 were propped up by Immunocore’s megaround, this year has seen a wider range of biotechs pull in sizable sums. Orchard Therapeutics’ £115 million series C leads the way, but rounds from companies such as Freeline and BenevolentAI aren’t too far behind. 

Yet the figures also show how far the U.K. has to go. The BIA wants the U.K. to establish itself as a global biotech hub to rival the San Francisco Bay Area and Massachusetts. The U.K. has the scientific credentials to support a bid for a seat at the top table but, despite the progress of recent years, it is still some way behind the U.S. clusters on the financial front. 

Over the first half of 2018, biopharmas based in Massachusetts raised (PDF) $2.7 billion (£2.1 billion) from VCs. With the caveat that methodological variations make comparing VC data from different sources inexact, that suggests biopharmas in the state raised as much in six months as their U.K. counterparts did across 2016, 2017 and the first eight months of 2018.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more